Zacks Investment Research
Silence Therapeutics (SLN) Upgraded to Buy: Here's Why
Silence Therapeutics PLC (SLN) received an upgrade to Zacks Rank #2 (Buy) based on upward trends in earnings estimates. The company's consensus estimate has increased 5.7% over the past three months, positioning it in the top 20% of Zacks-covered stocks for estimate revisions. The upgrade reflects improving business fundamentals that could drive near-term stock price appreciation.